Celebrating New Marketing Authorizations: Growing Our Global Impact
New global approvals mark another step forward for Venus Remedies—expanding access to trusted oncology and critical care medicines for patients across regions that need them most.
November 2025 has been a special month for us at Venus Remedies. We are proud to share that we have received several new Marketing Authorizations across important global markets. Each approval brings us one step closer to our goal of making advanced oncology and critical care medicines accessible to more patients around the world.
These approvals are not just regulatory milestones. They are moments that strengthen our belief in creating high-quality, affordable, and reliable treatments for global healthcare systems. Every authorization pushes us forward in our mission to serve patients who depend on critical therapies every single day.
Expanding Our Reach in Oncology and Critical Care
This month, we received approvals across multiple continents. Each one highlights our growing presence and our commitment to strong regulatory compliance.
Key Anticoagulant Authorization
We received approval for Enoxaparin 40 mg/0.4 ml, a key product used for anticoagulation and supportive care. This approval reinforces our expertise in both oncology and antibacterial therapies, helping us reach more patients who need trusted treatment options.
Strengthening Supportive Oncology Care
Our oncology portfolio continues to grow with the authorization of Leucovorin (50 mg/5 ml, 100 mg/10 ml, 300 mg/30 ml). Leucovorin is an important supportive therapy used in cancer treatment, and these approvals help us extend meaningful care to cancer patients across the region.
Expanding Chemotherapy Availability
We secured approval for Oxaliplatin 100 mg/50 ml, a widely used chemotherapy medicine. This authorization supports our ongoing work in expanding access to reliable oncology injectables in Southeast Asia and other high-need markets.
Enhancing ICU & Critical Care Access
Our critical care offerings have grown stronger with the approval of Dexmedetomidine, a key sedative therapy for ICU settings. This marks another step in building our presence in high-need therapeutic areas across the Middle East and beyond.
Strengthening Global Access to Cancer Care
We also reached an important milestone in El Salvador, where we received authorization for Fluorouracil 500 mg/10 ml. This is a vital chemotherapeutic drug used in treating several types of cancer. With this approval, we move closer to our long-term goal of improving cancer treatment access in Latin America.
Every authorization reflects our efforts to meet global quality standards. It shows the trust that regulatory authorities across regions continue to place in Venus Remedies. These achievements also help us expand conversations with partners, help hospitals strengthen their treatment options, and support patients who depend on timely and affordable medicines.
As we move ahead, we will continue to focus on science-driven innovation, regulatory excellence, and responsible expansion. These approvals open new pathways for deeper collaborations and help us reach healthcare systems that need dependable and advanced therapies.
